Formosa Laboratories Expands North American CRO/CDMO Footprint
Formosa Laboratories, Inc. announced that it has successfully completed its acquisition of SynChem, Inc., headquartered in the Chicago MSA suburb of Elk Grove Village. Founded in 1997, SynChem is a chemistry-based contract research organization (CRO) specializing in organic synthesis, process development and medicinal chemistry. Since its inception, SynChem has completed more than 4,500 projects for wide range of customers, including multi-national pharmaceutical companies, biotech companies, drug discovery companies and chemical and agrochemical companies. Founded in 1995, Formosa Laboratoriesap is a leading active pharmaceutical ingredients (API) supplier and contract development and... Read More »
Argosy Healthcare Partners Completes Recapitalization of Command Medical Products
Argosy Healthcare Partners (AHP) has announced a recapitalization and partnership with Command Medical Products to support its next stage of growth. This deal was facilitated and managed by MedWorld Advisors, a leading middle-market M&A advisory firm. Financial terms of the deal were not disclosed. Command Medical Products provides contract manufacturing services for the production of single-use disposable medical devices to global medical device original equipment manufacturers and life sciences customers. Headquartered in Ormond Beach, Florida and founded in 1987, the company provides customized clean room manufacturing of single-use medical devices leveraging key technologies,... Read More »
Novo Holdings Acquires Catalent for $16.5 Billion
Novo Holdings A/S announced that it will acquire Catalent, Inc. in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to the announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024. Catalent is a contract development and manufacturing organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. The company was formed in April 2007 when affiliates of the Blackstone Group acquired the core of the... Read More »
Arlington Capital Partners Announces Majority Investment in Afton Scientific
Arlington Capital Partners has announced a majority investment in Afton Scientific, a contract, development and manufacturing organization (CDMO) dedicated to sterile manufacturing of injectable pharmaceuticals. According to data captured in the LevinPro HC database, this acquisition marks the third CDMO transaction of the year. There were 21 CDMO transactions announced during 2023, and 39 during 2022. Based in Charlottesville, Virginia, Afton Scientific specializes in sterile injectable drug manufacturing as well as providing pre-sterilized vials and kits. The company performs aseptic fill-finish for products ranging from pre-clinical through commercial-scale manufacturing across various... Read More »
Ajinomoto Acquires Forge Biologics for $620 Million
Ajinomoto Co., Inc. and Forge Biologics announced on November 13 that they have entered into a definitive agreement by which Ajinomoto will acquire Forge Biologics in an all-cash deal for $620 million. Forge Biologics is a viral vector and plasmid contract development and manufacturing organization (CDMO) and clinical-stage therapeutics company, enabling access to potentially life-changing gene therapies by bringing them from concept to reality. All development and manufacturing is done at the Hearth, Forge Biologics’ 200,000 square-foot custom-designed cGMP facility in Columbus, Ohio, where the CDMO has more than 300 employees. Ajinomoto Co. is a global manufacturer of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
